Led · Equity · Jan 2026

Enogia develops compact micro-turbomachinery technologies that transform heat and select energy sources into electricity. The company is advancing a program called Turbo4Transition aimed at bringing low-carbon industrial solutions to market. With the newly obtained €5.4 million envelope, Enogia plans to accelerate technological development and industrialization to meet growing industrial needs for energy efficiency and emissions reduction. The firm emphasizes commercialization of its developments to create industrial-scale, decarbonization-focused products. The article does not disclose revenue, user, or other operating metrics.

Led · Convertible Note · Nov 2025

Crossject specialises in needle-free, high-pressure drug delivery through its proprietary Zeneo platform. Its flagship drug-device combination, Zepizure, is an auto-injectable midazolam intended for the rapid management of epileptic seizures. The company is currently preparing for an Emergency Use Authorization filing with the U.S. FDA, which analysts expect to be submitted by the end of 2025. To bridge operations until anticipated BARDA orders in early 2026, Crossject has been actively raising capital, including €5.7 million from a market placement before the summer and $11.3 million in September from the U.S. Biomedical Advanced Research and Development Authority (BARDA). The latest €5 million convertible bond financing extends its cash runway while minimising dilution, as full conversion would represent only about 3.65 % of outstanding shares. An Invest Securities analyst maintains a Buy rating with a €3.30 price target, citing sufficient funding to reach the next regulatory and commercial milestones.

Participated · Equity · Sep 2025

Hoffmann Green Cement has focused on reinforcing its financial position, carrying out an oversubscribed capital increase that generated gross proceeds of €7.93 million and net proceeds of about €7.6 million. The company issued 1,762,392 new shares at a subscription price of €4.50 per share. Funds managed by Vatel Capital were the largest participants, taking up 871,461 new shares for €3.92 million and an additional 17,806 shares for €80,127 after purchasing preferential subscription rights from founders Julien Blanchard and David Hoffmann. These founders together held 49.54 % of the company’s share capital as of 4 September 2025. Existing shareholders Eludom, Hestia and Isabelle Mommessin also subscribed, committing around €1 million, €525 k and €1 million respectively. The successful raise strengthens Hoffmann Green Cement’s balance sheet and provides fresh resources for its ongoing corporate objectives, though the article does not disclose further operating metrics or product details.